Filing Summary
Company: Vallon Pharmaceuticals, Inc. The request identifies GRI Bio, Inc., but the filing text names Vallon Pharmaceuticals, Inc. as the registrant.
Filing type and date: Form 8-K filed May 12, 2022, under Item 8.01 (Other Events). The report concerns additional results from the SEAL study evaluating ADAIR, the company’s proprietary abuse-deterrent formulation of immediate-release dextroamphetamine for attention deficit hyperactivity disorder.
Financial and Operating Metrics
This 8-K does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics. The filing text does not include the underlying study results or quantified operating data.
Material Changes Versus Prior Period
No comparable-period financial information or material period-over-period changes are disclosed.
Guidance, Outlook, Risks, and Unusual Items
- The company announced additional SEAL study results concerning the abuse potential of ADAIR.
- The filing does not provide the details of those results, management guidance, regulatory outlook, or commercialization expectations.
- Potential risks relating to clinical development, regulatory approval, abuse-deterrent performance, and commercial viability are not discussed in the filing text provided.
- The press release announcing the results was filed as Exhibit 99.1, but its contents are not included in the supplied filing text.
Key Facts to Verify
- Verify the registrant’s identity, because the supplied metadata lists GRI Bio, Inc. while the filing identifies Vallon Pharmaceuticals, Inc.
- Review Exhibit 99.1 for the actual SEAL study results, statistical significance, study design, and safety findings.
- Confirm any subsequent regulatory, clinical, financing, or commercialization developments involving ADAIR.
- Verify the company’s current trading symbol and corporate status, as the filing lists common stock trading under VLON on Nasdaq.